Advertisement

Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures

Sponsored by Pfizer

Phase Quota
Phase 3

The study will evaluate the long-term safety and tolerability of pregabalin in pediatric patients, age 1 month through 16 years, with partial onset seizures.

Study Start Date: May 2007

Estimated Completion Date: October 2013

Specialties: Pediatrics: Pediatric Neurology Physician Assistant: Pediatrics Neurology: Peds Neurology,Seizure Nursing: Pediatrics

Interventions

  • Drug: Pregabalin

Inclusion criteria

  • Partial onset seizures, incompletely controlled on 1-3 medications
  • At least 1 seizure per 28 days, on average
  • Completion of study A0081074

Exclusion criteria

  • Primary generalized seizures
  • Progressive CNS pathology
  • Failure to tolerate pregabalin in study A0081074

Study Locations And Contact Information

  • Pfizer Investigational Site, San Francisco California
  • Pfizer Investigational Site, Little Rock Arkansas
  • Pfizer Investigational Site, Phoenix Arizona
  • Pfizer Investigational Site, Buffalo New York
  • Pfizer Investigational Site, Gulf Breeze Florida
  • Pfizer Investigational Site, Guadalajara Jalisco
  • Pfizer Investigational Site, Seoul
  • Pfizer Investigational Site, Tampa Florida
  • Pfizer Investigational Site, San Antonio Texas
  • Pfizer Investigational Site, Houston Texas
  • Pfizer Investigational Site, Mobile Alabama
  • Pfizer Investigational Site, Mobile Alabama
  • Pfizer Investigational Site, Tampa Florida
  • Pfizer Investigational Site, Durham North Carolina
  • Pfizer Investigational Site, Jonesboro Arkansas
  • Pfizer Investigational Site, Springfield Missouri

Feature this Clinical Trial

Get your trial in front of 1000s of physicians and patients.
Visit ClinicalTrialsLocator.com to find out how you can feature this clinical trial.

Advertisement